Back

Standard dose of rivaroxaban in Asian patients with atrial fibrillation: 20ms vs.15mg? Off label dose reduction of rivaroxaban should be avoided

8 November 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session Sunday Anticoagulants ESC Premium Access ESC Asia with APSC & AFC

About the speaker

Photo
Doctor Hyung Ki Jeong

Wonkwang University Hospital, Iksan (Korea (Republic of))

31 More presentations in this session

Presentation thumbnail
Evaluation of coronary endothelial dysfunction by positron emission tomography: does gender make a difference
Doctor A. Aljizeeri (Riyadh, SA)
Abstract Slides
Presentation thumbnail
Fragmented QRS in prediction of ischemic heart disease diagnosed by stress cardiovascular magnetic resonance imaging
Doctor P. Yooprasert (Bangkok, TH)
Abstract
Presentation thumbnail
Identifying predictors for all-cause mortality at admission, 1 and 3 years after admission for acute decompensated heart failure amongst patients with atrial fibrillation.
Doctor H. Koh (Kuala Lumpur, MY)
Abstract Slides
Presentation thumbnail
Withdrawal of beta- blockers and ACE inhibitors after left ventricular systolic function recovery in patient with dilated cardiomyopathy randomized control trial
Doctor A. Bakhsh (Makkah, SA)
Abstract Slides
Presentation thumbnail
The differential impact of renal resistive index on future cardiovascular event in the hospitalised cardiovascular patients according to left ventricular ejection fraction: J-VAS study
Doctor P. Kotruchin (Khon Kaen, TH)
Abstract Slides

Access the full session

Session thumbnail
Poster Session Sunday

The Event

Event poster

ESC Asia with APSC & AFC

8 November - 10 November 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources